Skip to main content

Preoperative Frailty Tied to Postoperative Outcomes in Older Adults

Medically reviewed by Carmen Pope, BPharm. Last updated on June 19, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, June 19, 2024 -- Frailty is a significant predictor of noncardiac postoperative outcomes among Medicare beneficiaries, according to a study published online May 22 in Anaesthesia.

Chan Mi Park, M.D., M.P.H., from Hebrew SeniorLife in Boston, and colleagues used Medicare claims data from 1.0 million Medicare fee-for-service beneficiaries (2015 to 2019) to examine the association of perioperative frailty with mortality, 30-day readmission, and days at home after noncardiac surgical procedures of different physiological stress.

The researchers found that the cumulative incidence of mortality generally increased with Operative Stress Score category, ranging from 5.0 percent (Operative Stress Score 2) to 24.9 percent (Operative Stress Score 4) at 365 days. Increasing frailty was associated with mortality at 30 days (hazard ratios comparing moderate-to-severe frailty versus robust: 1.59 to 3.91) and at 365 days (hazard ratios, 1.30 to 4.04) within each category. Compared with variation by the operative stress category, the variation in postoperative outcomes by patients’ frailty level was much greater.

"These results emphasize routine frailty screening before major and minor noncardiac procedures and the need for greater clinician awareness of postoperative outcomes beyond 30 days in shared decision-making with older adults with frailty," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted June 2024

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.